Holt Stephen, Tetrault Jeanette
Section of General Internal Medicine, Department of Medicine, Yale School of Medicine, 1450 Chapel Street, New Haven, CT 06511, USA.
Section of General Internal Medicine, Department of Medicine, Yale School of Medicine, 367 Cedar Street, New Haven, CT 06510, USA.
Clin Liver Dis. 2016 Aug;20(3):429-44. doi: 10.1016/j.cld.2016.02.003.
Unhealthy alcohol use is common and routine screening is essential to identify patients and initiate appropriate treatment. At-risk or hazardous drinking is best managed with brief interventions, which can be performed by any provider and are designed to enhance patients' motivations and promote behavioral change. Alcohol withdrawal can be managed, preferably with benzodiazepines, using a symptom-triggered approach. Twelve-step programs and provider-driven behavioral therapies have robust data supporting their effectiveness and patients with alcohol use disorder should be referred for these services. Research now support the use of several FDA-approved medications that aid in promoting abstinence and reducing heavy drinking.
不健康饮酒行为很常见,常规筛查对于识别患者并启动适当治疗至关重要。对有风险或危险饮酒的最佳管理方法是进行简短干预,任何医疗服务提供者均可实施,其目的是增强患者的动机并促进行为改变。酒精戒断可以通过症状触发法进行管理,最好使用苯二氮䓬类药物。十二步康复计划和医疗服务提供者主导的行为疗法有充分的数据支持其有效性,酒精使用障碍患者应转介接受这些服务。目前的研究支持使用几种经美国食品药品监督管理局批准的药物,这些药物有助于促进戒酒和减少大量饮酒。